Clinical response (SRI) to treatment at weeks 12 and 24: ITT target population* analysis
| Lupuzor | |||
|---|---|---|---|
| Group 1 (200 μg every 4 weeks) | Group 2 (200 μg every 2 weeks) | Group 3 (placebo) | |
| Week 12 | n=42 | n=48 | n=44 |
| Responders, n (%) | 26 (61.9) | 23 (48.0) | 17 (38.6) |
| p=0.016 | p=0.18 | – | |
| Week 24 | n=42 | n=48 | n=46 |
| Responders, n (%) | 29 (69.1) | 30 (62.5) | 26 (56.5) |
| p=0.11 | p=0.28 | – | |
*Corresponds to all ITT patients having a clinical SLEDAI ≥6 at week 0.
p Values compare Lupuzor with placebo.
ITT, intention-to-treat; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SRI, SLE Responder Index.